ArticleFrontiers in oncology2026
Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endocrine therapy is a standard treatment strategy for hormone receptor-positive breast cancer, but the long-term impact on thyroid function remains unclear. This study evaluates changes in thyroid function among patients with early luminal breast cancer receiving adjuvant endocrine therapy compared to those with benign breast disease (BBD). Methods: This retrospective longitudinal cohort study included 53 patients with early luminal breast cancer (BC) who received adjuvant tamoxifen (TAM) or aromatase inhibitors (AIs), and 21 BBD controls. All participants had no history of thyroid disease, chemotherapy, or radiotherapy. Thyroid function parameters (TSH, FT3, FT4) were measured at baseline, 1 year, and 3 years post-surgery. Generalized linear mixed models (GLMM) were used to compare longitudinal changes between groups. Results: After 3 years of endocrine therapy, the BC group showed a significant increase in TSH (from 1.92 to 3.06 μIU/mL) and decreases in FT3 (from 4.90 to 4.14 pmol/L) and FT4 (from 18.35 to 15.26 pmol/L), whereas the BBD group showed no statistically significant changes over time. Significant group-by-time interactions were found for TSH (P = 0.018), FT3 (P = 0.016), and FT4 (P < 0.001). In subgroup analysis comparing TAM and AIs, a significant interaction was observed for FT4 (P = 0.022), indicating a greater decline in FT4 with TAM, while no significant differences were found for TSH (P = 0.508) or FT3 (P = 0.204). In subgroup analysis by tumor grade, no significant time-by-grade interactions were observed for TSH (P = 0.210), FT3 (P = 0.186), or FT4 (P = 0.073). Conclusions: Adjuvant endocrine therapy in early luminal breast cancer was associated with statistically significant alterations in thyroid function over 3 years, characterized by increased TSH and decreased FT3 and FT4. These alterations did not differ substantially by tumor grade. However, the small sample size and the complete collinearity between treatment type and menopausal status preclude drawing independent conclusions regarding the differential effects of TAM versus AIs. Further prospective studies are warranted to validate these observations and to explore their potential clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.